(264) Reasons of Discontinuation from Collagenase Clostridium histolyticum treatments in Peyronie’s Disease

Abstract Introduction Peyronie’s disease is an acquired fibrotic condition that impacts quality of life and sexual function. Intralesional Collagenase Clostridium histolyticum (CCH) the only FDA approved medication to correct curvature. The treatment consists 8 injections over 26 weeks previous studies indicate greater improvement associated with a number injections; however, reasons for early discontinuation are not well studied. Objective We aimed understand CCH in major academic system. Methods retrospectively reviewed charts PD patients from October 2018 2020 who underwent treatment. Complete four cycles two injections, each separated by approximately 5-6 weeks, total injections. Treatment completion was defined as receiving or stopping because curvature decreased <15 degrees. Patients did complete were contacted surveyed about discontinuation. Data gathered analyzed on Microsoft Excel. Results A 73 elected CCH. Only 43 (58.9%) completed all another 5 (6.8%) stopped due satisfaction, 48 (66%) reaching endpoint. There no significant difference age, duration symptoms Disease Questionnaire scores between those didn’t (Table 1). Similar dropped out first half second Out 30 (41.1%) discontinued therapy before 4 (13.3%) wanted try treatment, 6 (20%) experienced side effects, 3 (10%) had insurance issues, (16.7%) satisfied after few disappointed (26.7%) unable be return hospital 2). Conclusions found shifts financial/insurance status onset adverse events, such autoimmune flair, predictive dropouts our cohort. Most attempt so same surgeon but faster solution. Further, cohort, difficulty contacting biggest reason discontinuation; this likely skewed COVID19 pandemic relocated fewer elective treatments procedures. To reduce discontinuation, we propose counseling should focus potential speed change financial assistance. Disclosure No